# Study Evaluating PRA-027 Multiple Ascending Doses In Cycling And Postmenopausal Women

> **NCT00543790** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 48 (actual)

## Conditions studied

- Uterine Leiomyomata (Fibroids)

## Interventions

- **DRUG:** PRA-027

## Key facts

- **NCT ID:** NCT00543790
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2010-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00543790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00543790, "Study Evaluating PRA-027 Multiple Ascending Doses In Cycling And Postmenopausal Women". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00543790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*